Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.64 |
| ▸ | BCHE | P06276 | 10/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5620805 | 1.00 | TYR (0.64) | TYRBCHEMMP1MMP2MMP9 | |
| SCHEMBL7246057 | 0.87 | TYR (0.56) | TYRBCHE | |
| SCHEMBL6436676 | 0.83 | TYR (0.54) | TYRBCHE | |
| SCHEMBL6436683 | 0.83 | TYR (0.54) | TYRBCHE | |
| SCHEMBL27810920 | 0.82 | BCHE (0.61) | BCHEKCNA3F2PRSS1HDAC3 | |
| SCHEMBL6806375 | 0.82 | TYR (0.58) | TYRBCHE | |
| SCHEMBL6806377 | 0.82 | TYR (0.58) | TYRBCHE | |
| SCHEMBL16564484 | 0.82 | TYR (0.48) | TYRBCHEMMP1MMP2MMP9 | |
| SCHEMBL7238393 | 0.78 | TYR (1.00) | TYR | |
| SCHEMBL2473352 | 0.78 | NPSR1 (0.58) | TDP1F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3950046-B2 | — | — | 2007-07-25 | — | — | JP | claimed |
| JP-2004509154-A | — | — | 2004-03-25 | — | — | JP | claimed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | claimed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | claimed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | claimed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
| EP-1318974-A2 | RESORCINOL DERIVATIVES | Pfizer Products Inc. (US) | 2003-06-18 | — | — | EP | disclosed |
| US-6541473-B2 | Use as skin lightening agents; 4-(1,4-Dioxaspiro(4.5)dec-8-yl)-1,3-benzenediol for example | WARNER LAMBERT COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-20020137961-A1 | Resorcinol derivatives | PFIZER INC. | 2002-09-26 | — | — | US | disclosed |
| WO-2002024613-A2 | RESORCINOL DERIVATIVES | PFIZER PRODUCTS, INC. (US) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885BCHE 1952/4885MMP1 2085/4885 |
| US-20020137961-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885BCHE 1952/4885MMP1 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.